IDEAYA Biosciences (IDYA) EBITDA Margin (2020 - 2026)

IDEAYA Biosciences has disclosed EBITDA Margin across 7 years of filings, most recently posting 1544.21% for Q1 2026.

• EBITDA Margin for Q1 2026 came in at 1544.21%, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 61.2% (changed N/A YoY), and the FY2025 annual result was 51.32%, up 386621.0% from the prior year.
• EBITDA Margin came in at 1544.21% for Q1 2026 at IDEAYA Biosciences, down from 763.68% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 57.63% in Q3 2025 to a low of 1904.8% in Q4 2024.
• The 5-year median for EBITDA Margin is 482.33% (2022), against an average of 624.06%.
• Across the five-year window, EBITDA Margin slumped 107250 bps in 2024 and soared 114112 bps in 2025, its largest moves.
• IDEAYA Biosciences' EBITDA Margin stood at 573.6% in 2022, then sank by 45 bps to 832.3% in 2023, then slumped by 129 bps to 1904.8% in 2024, then soared by 60 bps to 763.68% in 2025, then plunged by 102 bps to 1544.21% in 2026.
• The last three EBITDA Margin figures came in at 1544.21% (Q1 2026), 763.68% (Q4 2025), and 57.63% (Q3 2025), per Business Quant data.